MedPath

Effects of Sucralose on Glucose Metabolism

Not Applicable
Completed
Conditions
Glucose Metabolism Disorders
Interventions
Other: Sucralose
Registration Number
NCT02589002
Lead Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Brief Summary

In this study the effects of sucralose on insulin sensitivity, beta-cell response and appetite regulating hormones will be evaluated.

Detailed Description

The consumption of non-nutritive sweeteners has a high prevalence. The effect of non-nutritive sweeteners in both beta-cell function and insulin resistance it is unknown.

Previous studies performed in animal models and humans with diverse characteristics have shown variable effects of different non-nutritive sweeteners in variables related to glucose metabolism.

Due to the high consumption of non-nutritive sweeteners it is relevant to know its effect in beta cell-function and insulin sensitivity.

In this study the effects of sucralose, a non-nutritive sweetener that is highly consumed in the population, on insulin sensitivity and beta-cell function will be evaluated.

54 participants with normal glucose tolerance, normal weight, and without chronic diseases with a low consumption of non-nutritive sweeteners will be included. The participants will be randomly assigned to consume sucralose or to a control group.

During the first visit an oral glucose tolerance test with 75 g of glucose will be performed. Fasting and 2-hour glucose will be measured in order to rule-out diabetes, abnormal fasting glucose, or glucose intolerance.

During the second visit a three-hour IV glucose tolerance test will be performed administering 0.3 g/kg of glucose and insulin 0.03 U/kg. Samples will be taken following the minimal model described by Bergman.

After this visit, the group assigned to receive sucralose will ingest 15% of the adequate daily intake (ADI) of sucralose and the control group will abstain of any non-nutritive sweetener consumption during 14 days. At the end of this period a third visit to repeat the IV glucose tolerance test will be performed.

Samples will be analyzed measuring glucose and insulin concentrations to evaluate acute insulin response (AIR), glucose effectiveness (SG), first phase pancreatic response (ф1), and second phase pancreatic response (ф2). In addition, hormones involved in appetite and satiety (leptin, ghrelin, and peptide tyrosine tyrosine) will be quantified at the beginning and end of the intervention.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
66
Inclusion Criteria
  • both genders
  • age between 18 and 55 years
  • body mass index ≥18.5 and <25 kg/m2
  • low consumption of non-nutritive sweeteners
Exclusion Criteria
  • diabetes or glucose intolerance
  • consumption of medications affecting insulin sensitivity (metformin, steroids, hormone replacement therapy, contraceptives)
  • intestinal disease such as malabsorption or previous intestinal resection
  • history of bariatric surgery
  • pregnancy or lactation
  • weight loss greater than 5% in the previous month

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SucraloseSucraloseIngestion of 15% of the ADI of sucralose daily during two weeks
Primary Outcome Measures
NameTimeMethod
Insulin sensitivityTwo weeks

Insulin sensitivity and pancreatic response estimated with the minimal model using a frequently sampled IV glucose tolerance test

Secondary Outcome Measures
NameTimeMethod
Leptin changeTwo weeks

Change in fasting leptin after sucralose ingestion

Glucagon like peptide (GLP-1) changeTwo weeks

Change in fasting GLP-1 after sucralose ingestion

Ghrelin changeTwo weeks

Change in fasting ghrelin after sucralose ingestion

Tyrosine-tyrosine peptide (PYY) changeTwo weeks

Change in fasting PYY after sucralose ingestion

Trial Locations

Locations (1)

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

🇲🇽

Mexico City, Distrito Federal, Mexico

© Copyright 2025. All Rights Reserved by MedPath